Recent News

  • Reading the Sacroiliac Joint Early: What MRI Reveals in axSpA

    Adela Castro, MD
    SI joint on green background
    Axial spondyloarthritis is notorious for being diagnosed late. Imaging is one of the best tools for catching it sooner, and the 2025 ASAS-SPARTAN revised classification criteria reflect that: the most heavily weighted variable is “MRI indicative of axSpA in the sacroiliac joints (SIJ).” Three new abstracts from the SPACE and SPARTAN CLASSIC cohorts show what that finding means in practice.
    Read Article
Antoni Chan MD (Prof) Tweet
@synovialjoints
Bimekizumab in overweight and obese PsA, pooled to 3 years: ACR50 41.0% with BMI 35 or more, 45.9% with BMI 30 or more, and 56.8% with BMI 27 to 30 plus comorbidity. Key finding: efficacy was sustained across BMI groups, with safety consistent with the overall population.
Adela Castro Tweet
@AdelaCastro222
CAR-T in SLE 2026 -Autologous CART: likely to achieve target faster (shorter time for SLEDAI/DORIS) -CD19-vs dual target (BCMA): no significant difference on SLEDAI -Pt w/ LN at baseline had steeper decline on SLEDAI -SAFETY: 64% of pts had CRS manageable (low grade) 95% of https://t.co/XyMOeoSpPL
Adela Castro Tweet
@AdelaCastro222
Double targeted therapy in refractory SpA/PsA Spanish multicentre cohort of 76 refractory SpA/PsA patients on double targeted therapy (DTT), median follow-up 15 months. -Most common: TNFi + IL-12/23i (30%), then TNFi + IL-17i (17%) -Mean ASDAS fell from 3.7 to about 2.0 by 6
Antoni Chan MD (Prof) Tweet
@synovialjoints
TriNetX, 7,083 matched PsA pairs: GLP1 RA prescription was associated with lower 3 year risk of joint effusion (RR 0.77), joint pain (RR 0.83) and steroid injection (RR 0.91). Key finding: GLP1 RA use was associated with improved joint outcomes; coded psoriasis was higher.
Brian Jaros, MD Tweet
@Dr_Brian_MD
The hottest treatment for TAK is... exercise? Online survey to TAK pt assessed exercise - 74% were rec'd exercise by MDs - 73% reported exercising Of 87% w/ arm involvement -> 35% improved sx w/ exercise Comparable to improvement attributed to meds! @Rheumnow #ACR26 #Abst1131
Adela Castro Tweet
@AdelaCastro222
SjD management: what is new? -Current therapies with low efficacy and no strong data. -Define target population: Important on treatment response What is new: -Ianalumab: B cell depletion. -Telitacicept: dual target Blyss+APRIL phase 3 showed promising results on both activity and https://t.co/ccJFr8Gb5t
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Eli Lilly and Company. All coverage content is independently selected by RheumNow and its faculty.

Video

Podcasts

  • ACR 2026 Daily Podcasts - Day1c
  • ACR 2026 Daily Podcasts - Day1b
  • ACR 2026 Daily Podcasts - Day1a
  • ACR 2026 RheumNow Day 1 Recap
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×